FDA Inspection
BAYER PHARMA, AGBAYER PHARMA, AG – FDA Inspection, Jun 6, 2024
Record Details
This FDA Inspection record concerns BAYER PHARMA, AG, with an inspection on June 6, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 1d238dca-b4e7-4c8f-8c8c-40de3cf1da86
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1282736
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of BAYER PHARMA, AG
9| Date | Classification | Office | Project area |
|---|---|---|---|
| August 27, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 24, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 3, 2017 | Not classified | Office of Inspections and Investigations | |
| January 24, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 13, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for BAYER PHARMA, AG
- FDA Inspection 1239178 - 2021-08-27
- FDA Inspection 1102816 - 2019-09-24
- FDA Inspection 1023408 - 2017-07-03
- FDA Inspection 1001127 - 2017-01-24
- FDA Inspection 889209 - 2014-05-13
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.